Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBAY 9835 New
Description: Potent ADAMTS7 and ADAMTS12 inhibitor
Chemical Name: 5,6-Difluoro-N-[[(4S)-4-(1-methyl-1H-pyrazol-5-yl)-2,5-dioxo-4-imidazolidinyl]methyl]-4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamide
Purity: ≥98% (HPLC)
Biological Activity for BAY 9835
BAY 9835 is a potent ADAMTS7 and ADAMTS12 inhibitor (IC50 values are 6 nM and 30 nM, respectively). BAY 9835 is selective over other metalloproteases (ADAMTS4, ADAMTS5, ADAM8, ADAM10, ADAM17, MMP2, MMP12, MMP14, MMP15). BAY 9835 is the first orally bioavailable ADAMTS7 inhibitor.
Licensing Information
This compound is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY 9835 probe summary on the SGC website.
Technical Data for BAY 9835
| M. Wt | 493.39 |
| Formula | C22H16F5N5O3 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 3032487-31-0 |
| PubChem ID | 170836223 |
| InChI Key | LPQXZOJIUVOCAL-NRFANRHFSA-N |
| Smiles | O=C(C1=C(C2=CC=C(C=C2)C(F)(F)F)C(F)=C(C=C1)F)NC[C@@]3(C4=CC=NN4C)NC(NC3=O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BAY 9835
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 49.34 | 100 |
Preparing Stock Solutions for BAY 9835
The following data is based on the product molecular weight 493.39. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.03 mL | 10.13 mL | 20.27 mL |
| 5 mM | 0.41 mL | 2.03 mL | 4.05 mL |
| 10 mM | 0.2 mL | 1.01 mL | 2.03 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.41 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for BAY 9835
References for BAY 9835
References are publications that support the biological activity of the product.
Meibom et al (2024) BAY-9835: Discovery of the first orally bioavailable ADAMTS7 inhibitor. J.Med.Chem. 67 2907 PMID: 38348661
If you know of a relevant reference for BAY 9835, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BAY 9835, BAY 9835 supplier, BAY9835, BAY-9835, potent, selective, orally, bioavailable, ADAMTS7, ADAMTS12, metalloprotease, MMPs, atherogenesis, metalloproteinases, inhibits, inhibitors, adams, ADAMs, Matrix, Metalloprotease, 8826, Tocris Bioscience
Citations for BAY 9835
Citations are publications that use Tocris products.
Currently there are no citations for BAY 9835. Do you know of a great paper that uses BAY 9835 from Tocris? Please let us know.
Reviews for BAY 9835
There are currently no reviews for this product. Be the first to review BAY 9835 and earn rewards!
Have you used BAY 9835?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.